Drug Profile

Peginterferon beta-1a - Biocad

Alternative Names: amPEG-IFNß-1a - Biocad; BCD 054; TENEXIA

Latest Information Update: 20 Mar 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Biocad
Class Interferons
Mechanism of Action Immunomodulators; Interferon beta stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase II/III Multiple sclerosis

Most Recent Events

24 Sep 2025 Peginterferon beta-1a is still in phase-II/III for Multiple sclerosis in Russia (IM) (NCT02744222)
24 Sep 2025 Efficacy data from a phase-II/III trial in Multiple sclerosis presented at the 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS-2025)
30 Sep 2020 No development reported - Phase-II for Multiple sclerosis in Russia (SC)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com